Glumine

Quick links to important sections

Glumine

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glumine

Quick Facts

Property Description
Active Ingredient Thiamine Hydrochloride (Vitamin B1)
Form Oral tablet, Capsule, Injectable solution
Pharmacological Class B Vitamins (Water-Soluble Vitamins)
Common Use Restitution of Thiamine deficiency
Origin Synthetically derived

What Type of Medicine Is Glumine?

Glumine is a single-ingredient medicinal product containing Thiamine Hydrochloride, which is the stable salt form of Thiamine, also known as Vitamin B1. This substance is classified as a vital B Vitamin and a water-soluble vitamin. Thiamine is recognized as essential for human health, with a primary role as supportive nutritional supplementation rather than a direct pharmacological agent. This characteristic sets it apart from fat-soluble vitamins, which are stored; Thiamine is rapidly used by the body and requires frequent replenishment.


Composition, Origin, and Available Forms

The definitive active ingredient in Glumine is Thiamine Hydrochloride (C₁₂H₁₇ClN₄OS · HCl). Although Thiamine exists naturally as an essential micronutrient, the pharmaceutical ingredient used in Glumine is typically synthetically derived to guarantee the uniform purity and concentration required for medical use. Glumine is made available in several dosage forms, notably including the oral tablet and the sterile injectable solution. This dual route availability for oral and parenteral administration is a key feature, allowing for flexible support in patients with, for instance, severe malabsorption.


Glumine’s General Purpose for Metabolism

Glumine’s general purpose is to replenish the body’s levels of Thiamine to maintain critical energy pathways, particularly for high-demand organs. In the body, Thiamine is converted into the active coenzyme, Thiamine diphosphate (ThDP), which is indispensable for the metabolism of carbohydrates and the generation of cellular energy. This essential metabolic role makes the substance vital for the smooth functioning of the nervous system and the myocardium (heart muscle), ensuring these systems have the continuous energy supply they require.

Regulatory References

  1. Thiamine Hydrochloride Injection, USP Monograph
  2. Thiamine on WHO Essential Medicines List

What side effects are possible with Glumine?

Possible Side Effects and Safety Information

Glumine (Thiamine Hydrochloride) is a vitamin preparation whose official safety profile, particularly for the injectable form, details adverse reactions classified by regulatory bodies. The majority of these events are categorized as having a Frequency Not Known (meaning they cannot be estimated from available data) but are documented by System-Organ Class (SOC) categories.


Documented Adverse Reactions and Organ Systems

Adverse reactions listed in regulatory documents span several body systems, including:

System Organ Class Documented Reactions Include
Immune System Disorders Hypersensitivity reactions, Anaphylactic reactions
Gastrointestinal Disorders Nausea, Vomiting, Abdominal pain
Skin Disorders Urticaria (hives), Pruritus (itching), Erythema, Sweating
Vascular Disorders Hypotension, Collapse, Cyanosis
Nervous System Disorders Restlessness, Headache, Dizziness
General & Administration Site Feeling of warmth, Weakness, Injection site tenderness/pain

Serious Adverse Reactions and Safety Constraints

The most significant safety consideration is the potential for serious, life-threatening events, particularly following parenteral administration. These are documented in regulatory sources and include Anaphylactic Shock, Cardiovascular Collapse, Death, and Pulmonary Edema.

  • Safety Restriction: Glumine is contraindicated in individuals with a known history of hypersensitivity to Thiamine Hydrochloride or to any of the product's excipients.
  • Exposure Pattern Note: Regulatory labeling indicates that the risk of severe allergic reactions may increase with repeated parenteral (injection) administration of the drug.

Overdose and Emergency Response

The official regulatory profile for Glumine (Thiamine Hydrochloride) draws a distinction between the substance’s generally low oral toxicity and the more severe risks documented following repeated parenteral administration (injection). Severe toxicity is not expected from high oral doses, as excess Thiamine is rapidly excreted in the urine. However, overdose or severe sensitivity reactions primarily related to the injectable form have been associated with life-threatening outcomes.


Documented Manifestations and Severe Outcomes

The officially documented manifestations include gastrointestinal distress such as mild transient nausea and diarrhea, as well as cutaneous signs like pruritus (itching), urticarial, and a sensation of swelling of the entire body. The most critical outcomes listed in the regulatory documents are life-threatening anaphylactic shock, pulmonary oedema, haemorrhage into the gastrointestinal tract, and collapse.


Required Emergency Action

In the event of an overdose or suspected severe reaction presenting these symptoms, regulatory guidance mandates that patients seek immediate medical attention by contacting a doctor or hospital immediately for consult. Treatment for overdosage is defined as symptomatic and supportive, as no specific antidote is known. A separate warning exists regarding the risk of aluminum toxicity from prolonged parenteral use in premature neonates and those with impaired kidney function.

Therapeutic Uses of Glumine

What Glumine Treats: Main Uses and Benefits

Glumine is commonly used to help manage the symptoms of Thiamine deficiency and its severe consequences across several critical domains, generally focusing on symptomatic relief and physiological support. The medication is considered relevant for treating or preventing severe deficiency syndromes, specifically including conditions like Wernicke encephalopathy and different forms of Beriberi (Wet and Dry).


Key Therapeutic Applications

Glumine is used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. The medication plays a role in managing symptom clusters that may become intense or disruptive, such as acute neurological deficits (confusion, lack of coordination) and cardiovascular distress (fluid accumulation, rapid heart rate). This use generally helps to manage symptoms related to heightened physiological activity.

“This application generally provides supportive relief that may assist with the management of severe symptoms and contribute to maintaining functional stability.”

In high-risk patient groups, like those with malabsorption issues or chronic alcoholism, the medication plays a role in managing symptoms by offering supportive relief, which may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Support for Neurological Symptom Management
Glumine may assist with maintaining functional stability in conditions presenting with symptoms of increased neurological activity, such as ataxia and acute confusion.

Eligibility and Restrictions for Use

Who Can and Cannot Use Glumine? - Official Regulatory Information

The eligibility for Glumine (Thiamine Hydrochloride) is determined by officially documented rules and population restrictions as outlined in regulatory labeling.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults with established Thiamine deficiency, including patients diagnosed with Wernicke encephalopathy or Beriberi. Use is indicated for patients who cannot take thiamine orally due to severe malabsorption.
Populations for whom use is contraindicated Patients with a known history of sensitivity/hypersensitivity to thiamine or to any of the product’s non-active ingredients (excipients).
Age-related eligibility rules Use in children under 12 years requires specialist recommendation. Some specific oral formulations are not recommended for children under three years of age. Older adults may require dosage adjustment due to the greater frequency of decreased organ function.
Condition-specific eligibility rules Use of the parenteral (injectable) formulation must be restricted or closely monitored in patients with impaired kidney function due to the risk of aluminum accumulation with prolonged treatment.
Pregnancy and lactation eligibility status The injectable form holds an FDA Pregnancy Category A classification; it is indicated for neuritis of pregnancy if vomiting is severe. Caution is advised during lactation, as it is not known whether the drug is excreted in human milk.

Eligibility Classifications (High-Level)

Classification Regulatory Basis
Eligibility severity classification Absolute Contraindication (Hypersensitivity), Conditional Restriction (Renal Impairment/Parenteral Administration), Not Recommended (Specific Pediatric Use).
Regulatory basis FDA Label, Summary of Product Characteristics (SmPC), NIH/DailyMed.

Resulting Eligibility Structure

Official regulatory documents define Glumine’s use by primarily establishing eligibility for adults with documented thiamine deficiency, while strictly prohibiting use in individuals with known hypersensitivity to the drug or its components. The regulatory profile also places restrictions on the injectable form in patients with impaired kidney function and provides specific age-related constraints for use in pediatric populations.

What should I know about interactions with other medicines?

Glumine Interactions with other medicines and products

The official regulatory documents describe specific interaction patterns that can alter Glumine's availability and effectiveness. These interactions are classified based on the mechanism of interference or the resulting constraints on administration.


Official Interaction Statements:

  • Co-administration with agents classified as Thiamine Antagonists, such as fluoropyrimidines (e.g., 5-Fluorouracil) or Ifosfamide, may officially neutralize Glumine’s systemic effect through pharmacodynamic interference.
  • Certain loop diuretics (e.g., Furosemide) can lead to reduced Glumine exposure due to a pharmacokinetic interaction that increases urinary thiamine excretion.
  • Oral Glumine co-administration with the cationic binding agent Patiromer requires a mandatory separation of administration by at least 3 hours to mitigate the risk of absorption interference.
  • For the injectable solution, a physical incompatibility restriction applies: Glumine must not be co-administered in the same container with solutions of moderately alkaline drugs, including Acetazolamide.
  • Chronic alcohol consumption is officially documented as a substance interaction that impairs the body’s processing and utilization of thiamine.
  • In specific at-risk populations, the sequence of administration is a constraint: Intravenous Glucose should generally not precede Glumine due to the risk of rapid thiamine depletion.

This structure highlights substances that cause effect neutralization, reduce exposure via clearance, or necessitate dose timing constraints, as defined by government health authorities.

Mechanism of Action

How Glumine Works: Mechanism of Action

Glumine (Thiamine Hydrochloride) functions by providing the precursor required to overcome a metabolic block at the cellular level, acting as a precursor to the essential coenzyme Thiamine Diphosphate (ThDP). Its mechanism is defined by the essential coenzyme role of its active form, ThDP, in maintaining metabolic flow.


Action on Bioenergetic Pathways

The mechanism directly engages enzyme complexes critical for cellular energy production, primarily the Pyruvate Dehydrogenase (PDH) and alpha-Ketoglutarate Dehydrogenase (KGDH) complexes. ThDP is required to catalyze the oxidative decarboxylation of alpha-keto acids, which are mandatory entry points for glucose metabolites into the Tricarboxylic Acid (TCA) Cycle (Krebs Cycle). This interaction enables sustained aerobic respiration and ATP synthesis, alleviating the energy blockade that occurs without the coenzyme.


Effect on High-Demand Tissue Metabolism

By reactivating the TCA cycle, the mechanism enables the continuous and efficient supply of cellular energy specifically for the extbfCentral Nervous System (CNS) and the Myocardium. These tissues have an extremely high and continuous metabolic demand, making them uniquely vulnerable to the accumulation of toxic intermediary metabolites like pyruvate and lactate when the coenzyme is absent. The resulting physiological effect is a direct consequence of metabolic flow being restored to these critical organ systems.

Dosage and Administration Information

Glumine is administered through two primary routes: the oral route (tablet or capsule) for mild deficiency or long-term maintenance, and the parenteral route (intramuscular or slow intravenous injection/infusion) for acute or severe deficiency states where rapid tissue replenishment is necessary.

Official Administration Guidelines

Category Official Instruction (Label-Based)
Route of Administration Oral or Parenteral (IM or slow IV).
Dosing Schedule Acute Deficiency: Parenteral doses typically range from 10 mg to 20 mg three times daily (TID) for Beriberi, or an initial 100 mg IV for Wernicke’s encephalopathy. Higher doses up to 500 mg TID are cited for severe cases. Oral Maintenance: Typically 5 mg to 10 mg once daily, used following the acute phase.
Preparation & Timing The injectable solution for IV administration must be diluted and delivered as a slow infusion, typically over 30 minutes, and should not be administered as a direct, undiluted IV injection. In acute care, Glumine should be administered before or concurrently with intravenous glucose to manage deficiency.
Course Duration Parenteral therapy is generally a short-term course, lasting up to two weeks or until the patient transitions to a regular oral diet.

Procedural Structure

The official use of Glumine follows a structured, two-phase protocol that dictates the administration method and dose. Treatment typically begins with the high-frequency parenteral route (IM or IV) to achieve rapid support. This is followed by a switch to the lower-dose, once-daily oral tablet for long-term management and tissue saturation until the underlying risk factors for deficiency have been resolved.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Glumine

Evidence for Use in Treating Wernicke Encephalopathy

Glumine was studied in research contexts involving acute neurological symptoms associated with severe Thiamine deficiency, a condition characterized by functional limitations such as acute confusion and lack of coordination. The existing evidence for this use is drawn from a combination of historical observational studies and small clinical trials which have tracked patients during periods of heightened symptom activity.

Studies explored how symptoms evolved in the observed populations, focusing on outcomes related to systemic or functional imbalance such as specific eye movement difficulties and changes in mental status. Historical and observational findings describe patterns observed in the studies related to the short-term neurological outcomes. However, when comparing different dosing strategies in some recent trials, findings were mixed regarding whether high doses led to different clinical patterns compared to standard doses.

What remains uncertain is the optimal long-term approach. Long-term effects are not fully established regarding the lasting course of cognitive function. The existing research mainly focuses on the acute phase, and data for certain groups remain insufficient to define consistent long-term patterns following the initial intervention.


Evidence for Use in Treating and Preventing Beriberi

Glumine was studied for conditions associated with acute or disruptive episodes such as Beriberi, a severe deficiency syndrome that manifests either with neurological symptoms (Dry Beriberi) or cardiovascular symptoms (Wet Beriberi). The evidence is primarily derived from historical observational data and case reports, with fewer recent large-scale clinical trials.

Research highlights changes measured during the study period for both forms of the condition. For Wet Beriberi, clinical records describe patterns observed in the studies related to the evolution of outcomes monitoring physiological strain in the heart and circulatory system. For Dry Beriberi, studies describe the typically slow and variable progress of outcomes related to peripheral neuropathy symptoms (nerve damage). The evidence contributes to understanding the distinct symptom patterns across these different manifestations of deficiency.

Key Studies & References

  1. THIAMINE HYDROCHLORIDE injection label (Official FDA Drug Monograph)
  2. WHO Model List of Essential Medicines (Used for context on vital role and global uses like Beriberi)
  3. Thiamine Deficiency: MedlinePlus Medical Encyclopedia (For foundational context on deficiency and Beriberi)

Frequently Asked Questions (FAQ)

Common questions about Glumine (FAQ)

Q: Is Glumine used for conditions other than the primary one mentioned?

A: Glumine is primarily indicated for the restitution of Thiamine deficiency, which includes conditions such as Wernicke encephalopathy and Beriberi. Official regulatory sources define the approved scope of use primarily around addressing these deficiency states.

The focus of regulatory documents is on the approved uses related to deficiency states, and official product labeling generally restricts its main purpose to nutritional support for established Thiamine deficiency.

Q: Is Glumine the same type of medicine as [A common competitor drug name]?

A: Glumine is a single-ingredient medicinal product containing Thiamine Hydrochloride, which is classified as a B Vitamin and a water-soluble vitamin. Official information defines its type based on its active ingredient's chemical structure and nutritional role.

Since its active ingredient is Thiamine Hydrochloride, Glumine is considered the same type as generic Vitamin B1 preparations. The comparison of Glumine to specific competitor drugs is not a point covered in official product documentation.

Q: How quickly should I expect to notice any effects from Glumine?

A: The onset of action is not precisely defined in regulatory summaries as a patient-noticeable timeline. For acute and severe deficiency states requiring rapid tissue replenishment, the parenteral (injection) route is used for immediate support.

Response can vary based on the severity of the deficiency and the route of administration, as documented in clinical experience.

Q: What are the most commonly reported side effects of Glumine?

A: Official drug labels list several documented adverse reactions across various body systems, including nausea, vomiting, and skin reactions like hives. However, regulatory documents for many of these documented events indicate their frequency is 'Not Known,' meaning the most common side effects cannot be reliably estimated from available data.

Serious allergic reactions, especially following injection, are a documented safety consideration.

Q: Is it normal to feel [A non-specific feeling] when first starting Glumine?

A: Regulatory information documents potential feelings such as a 'feeling of warmth' and 'weakness' under the list of possible adverse reactions. The list documents possible reactions but does not define what is considered a 'normal' initial experience.

Any new or concerning feelings should be reported to a healthcare professional, as determining the significance of a reaction requires clinical evaluation.

Q: Does Glumine interact with blood pressure medication?

A: Regulatory documents detail a specific interaction with certain loop diuretics, a type of blood pressure medication, which can lead to reduced Glumine exposure. Beyond this specific class, official product information does not generally list widespread interactions with most other common blood pressure drugs.

It is important to inform a healthcare provider of all medications being taken, including any for blood pressure management.

Q: Is there a patient information leaflet (PIL) I can read about Glumine?

A: Yes, patient-facing information is created for Glumine and its active ingredient, Thiamine Hydrochloride. Documents such as Patient Information Leaflets (PIL) or Medication Guides are published by regulatory bodies and manufacturers.

These resources provide the specific safety and usage information as defined by regulatory standards.

Q: How does Glumine affect [specific body system, e.g., the liver]?

A: Glumine's mechanism of action primarily supports energy production for high-demand organs like the Central Nervous System and the Myocardium (heart muscle).

While the liver is where thiamine is metabolized and stored, official documents focus more on the drug's effects on the nervous and cardiovascular systems rather than specific warnings related to liver function.

Q: Can Glumine affect my ability to drive or operate machinery?

A: Adverse reactions listed in regulatory documents include headache and dizziness, which could potentially impair attention or motor skills. However, official product labeling generally states that Glumine is not known to affect the ability to drive or use machines.

If dizziness or other nervous system effects are experienced after administration, patients should follow their healthcare provider’s instructions regarding driving and operating machinery.

Q: Has Glumine been studied in diverse patient populations?

A: Regulatory summaries of the research evidence indicate that Glumine's efficacy is established through a combination of historical observational studies and small clinical trials focused on patients with Thiamine deficiency.

These summaries may not always contain specific breakdowns regarding the demographic diversity (e.g., race or ethnicity) of the patients included in the core studies used for regulatory approval.

Q: Can Glumine cause changes in mood or behavior?

A: Adverse reactions listed under nervous system disorders include restlessness. However, official product information does not explicitly list common mood or psychiatric symptoms, such as anxiety or depression, as side effects of Glumine.

It is important to note that the underlying deficiency Glumine treats can itself lead to symptoms like mental depression.

Q: Why must Glumine be used with caution in patients with heart conditions?

A: Glumine (Thiamine) is critical for the energy supply of the heart muscle (myocardium), and deficiency is directly associated with cardiovascular symptoms (Wet Beriberi). Regulatory information details that hypotension and vascular collapse are potential, though rare, adverse reactions.

Although Glumine treats deficiency that affects the heart, general eligibility rules focus restrictions on kidney impairment rather than non-deficiency heart disease. Caution is advised when administering parenteral doses.

Q: Are there specific patient monitoring recommendations while using Glumine?

A: Yes, specific monitoring is officially recommended in certain circumstances. For patients with impaired kidney function, the use of the injectable formulation must be closely monitored due to the risk of aluminum accumulation.

For general administration, monitoring for adverse reactions, especially hypersensitivity, is standard practice, particularly with repeated injections.

Q: Is Glumine safe for people with diabetes?

A: Glumine, a nutritional supplement, is generally considered safe for use in the diabetic population. The primary regulatory constraint related to blood sugar is administrative: Intravenous Glucose should generally not be given immediately before Glumine.

Official information notes the essential role of thiamine in carbohydrate metabolism, which is a process relevant to the management of diabetes.

Q: How long does Glumine stay in the body after stopping use?

A: Glumine (Thiamine) is a water-soluble vitamin, meaning it is not stored in the body in large amounts. Regulatory and nutritional sources confirm that any amount in excess of the body's immediate requirements is rapidly excreted in the urine as unchanged thiamine or its metabolites.

Because of its rapid turnover, the body requires frequent replenishment.

Q: Are there any common supplements or vitamins that should not be taken with Glumine?

A: Official regulatory guidance advises patients to consult a healthcare professional before combining Glumine with any other supplements or herbal remedies. This is primarily to avoid potential high vitamin intake, as some combination supplements may already contain thiamine.

Regulatory guidance advises professional consultation to review individual product labels and prevent unintended high vitamin intake.

Q: What if I accidentally miss a dose of Glumine?

A: General instructions found in official patient information guides advise that if an oral dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the patient should skip the missed dose.

Patient information states that a double or extra dose should not be taken to compensate for a missed one.

Q: Are generic versions of Glumine available?

A: Yes, Glumine's active ingredient, Thiamine Hydrochloride, is a common vitamin preparation. The higher-strength injectable solution and oral tablets are widely available in generic formulations, which are listed in official product databases like DailyMed.

Q: Does taking Glumine affect lab test results?

A: Yes, official regulatory safety information notes that Glumine can interfere with the accuracy of certain laboratory test results. Specifically, Thiamine may cause false positive results for urobilinogen tests using the Ehrlich’s reaction.

It is important that lab personnel and all healthcare providers are informed when a patient is taking Glumine before blood or urine tests are conducted.

Q: Are there any food restrictions while using Glumine?

A: Regulatory guidelines and product labels do not mandate specific food restrictions while taking Glumine. The primary dietary focus in official documentation is the constraint involving chronic alcohol consumption, which impairs thiamine processing and utilization.

While certain raw foods contain thiamine-deactivating enzymes, this is generally not a concern unless consumption is very high in the context of severe deficiency.

Q: What should I do if I experience a potential interaction between Glumine and another medicine?

A: Regulatory documents and patient safety warnings instruct that if a patient suspects or experiences an adverse reaction or interaction, they should seek immediate advice from a healthcare professional.

Adverse events and potential interactions can be reported to the appropriate national health authority (such as the FDA or MHRA) via official reporting schemes.

Q: Is it necessary to take Glumine at the exact same time every day?

A: Official guidelines for oral Glumine recommend taking the medication at regular intervals for best results, as this helps ensure stable Thiamine levels in the body over time.

While absolute precision is not usually mandated, maintaining consistency in the daily schedule is generally advised.

Q: Does Glumine need a prescription?

A: Glumine (Thiamine Hydrochloride) is available in both over-the-counter (OTC) supplement doses and high-strength prescription-only formulations. The injectable solution and high-dose tablets used for treating diagnosed severe deficiency states require a prescription.

Q: Does Glumine interact with herbal remedies?

A: Official regulatory documents and patient safety guidance advise that patients should consult a doctor or pharmacist before taking Glumine with any herbal remedies. This precaution is necessary due to the potential for unforeseen interactions or the risk of consuming ingredients that may already contain Thiamine.

Q: Why is Glumine a controlled substance (if applicable)?

A: Glumine's active ingredient, Thiamine Hydrochloride, is classified as a B Vitamin. Official government classification records confirm that Glumine is not listed as a controlled substance under the U.S. Controlled Substances Act or similar international regulatory frameworks.

Q: Does Glumine affect sleep patterns?

A: Changes to sleep patterns are not listed as an adverse reaction to the medicine itself in regulatory documents. However, the symptoms of Thiamine deficiency, which Glumine is prescribed to treat, can include fatigue and malaise, which may improve upon successful treatment.

Q: Does Glumine cause weight gain or loss?

A: Weight changes are not listed as a common or known side effect of Glumine therapy in regulatory documents. However, unintentional weight loss is a documented symptom of the underlying Thiamine deficiency that the medicine is used to treat, and therapy aims to restore normal physiological function.

How should Glumine be stored and disposed of?

How to Store and Dispose of Glumine (Thiamine HCl)

Storage Requirement Official Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Container Keep the medication in its original container and ensure the container is tightly closed.
Light/Freezing Protect the injectable solution from light. The injectable solution must not be frozen.
Child Safety Store the medicine out of the sight and reach of children.

Glumine (Thiamine HCl) storage conditions are defined to maintain the stability of the active ingredient. The product must be kept in its original, tightly closed container and protected from conditions outside the specified temperature range. Unused or expired Glumine must be disposed of according to local regulatory requirements; it should not be thrown into household waste or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glumine found in:

A-Z Index: